Literature DB >> 15829256

Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter.

Javier Garzón1, María Rodríguez-Muñoz, Pilar Sánchez-Blázquez.   

Abstract

In the CNS, several regulators of G-protein signalling (RGS) modulate the activity of mu-opioid receptors. In pull-down assays performed on membranes from mouse periaqueductal gray matter (PAG), mu-opioid receptors co-precipitated with delta-opioid receptors, Gi/o/z/q proteins, and the regulators of G-protein signalling RGS4, RGS9-2, RGS14, RGSZ1 and RGSZ2. No RGS2, RGS7, RGS10 and RGS11 proteins were associated with the mu receptors in these PAG membranes. In mice, an intracerebroventricular dose of 10 nmol morphine produced acute tolerance at mu receptors but did not disrupt the co-precipitation of mu-delta receptor complexes. However, this opioid reduced by more than 50% the co-precipitation of G alpha i/o/z subunits with mu receptors, and altered their association with some of the RGS proteins at 30 min, 3 h and 24 h after its administration. The association of RGS9-2 with mu receptors diminished by 30-40% 24 h after the administration of morphine, while that of RGSZ2 and of RGSZ1 increased. Morphine treatment recruited RGS4 to the PAG membranes, and 30 min and 3 h after the opioid challenge its association with mu receptors had increased. However, 24 h after morphine administration, the co-precipitation of RGS4 had decreased by about 30%. The opioid produced no change in the membrane levels of RGS9-2, RGS14, RGSZ1 and RGSZ2. Thus, in PAG synaptosomal membranes, a dynamic and selective link exists between, mu-opioid receptors, Gi/o/z proteins and certain RGS proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829256     DOI: 10.1016/j.neuropharm.2005.01.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  22 in total

1.  The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Ana Vicente-Sánchez; Esther Berrocoso; Javier Garzón
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

2.  RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.

Authors:  Sevasti Gaspari; Valeria Cogliani; Lefteris Manouras; Ethan M Anderson; Vasiliki Mitsi; Kleopatra Avrampou; Fiona B Carr; Venetia Zachariou
Journal:  Neuropsychopharmacology       Date:  2017-01-11       Impact factor: 7.853

3.  Phosphorylation of unique C-terminal sites of the mu-opioid receptor variants 1B2 and 1C1 influences their Gs association following chronic morphine.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  J Neurochem       Date:  2019-10-20       Impact factor: 5.372

4.  Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

Authors:  M F Bird; R S Vardanyan; V J Hruby; G Calò; R Guerrini; S Salvadori; C Trapella; J McDonald; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2015-02-13       Impact factor: 9.166

Review 5.  Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS.

Authors:  Javier Garzón; María Rodríguez-Muñoz; Elena de la Torre-Madrid; Pilar Sánchez-Blázquez
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

Review 6.  Regulators of G Protein Signaling in Analgesia and Addiction.

Authors:  Farhana Sakloth; Claire Polizu; Feodora Bertherat; Venetia Zachariou
Journal:  Mol Pharmacol       Date:  2020-05-30       Impact factor: 4.436

7.  Regulators of G-Protein Signaling (RGS) Proteins Promote Receptor Coupling to G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channels.

Authors:  Kylie B McPherson; Emily R Leff; Ming-Hua Li; Claire Meurice; Sherrica Tai; John R Traynor; Susan L Ingram
Journal:  J Neurosci       Date:  2018-08-27       Impact factor: 6.167

8.  Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling.

Authors:  Pilar Sánchez-Blázquez; María Rodríguez-Muñoz; Javier Garzón
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

9.  Analysis of candidate genes for morphine preference quantitative trait locus Mop2.

Authors:  G A Doyle; C L Schwebel; S E Ruiz; A D Chou; A T Lai; M-J Wang; G G Smith; R J Buono; W H Berrettini; T N Ferraro
Journal:  Neuroscience       Date:  2014-07-22       Impact factor: 3.590

10.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.